article thumbnail

From Healing to Harm: The Unintended Consequences of Polypharmacy in Seniors

PharmD Live

People over 65 make up only 14% of the population but account for 56% of hospitalizations for adverse drug events (ADEs) (Agency for Healthcare Research and Quality, AHRQ, 2021). Emergency Hospitalizations for Adverse Drug Events in Older Americans. Clinical Consequences of Polypharmacy in Elderly. References: Budnitz, D.

article thumbnail

Alzheimer’s drug requires strengthened pharmacovigilance approach

European Pharmaceutical Review

A paper published by the Drug Safety Research Unit (DSRU) in the British Journal for Clinical Pharmacology , has asserted the need for ongoing assessment of the safety and effectiveness of the Alzheimers drug lecanemab in the real-world clinical setting.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

9th PREDiCT: Tumor Models Cell Therapy Summit

pharmaphorum

Taking place as a fully interactive digital event, this is y our chance to hear the latest advances and innovations in the preclinical cell therapy space. Download the full event guide here for more information on what you can look forward to.

article thumbnail

FDA Issues “Cliffs Notes”-style Guidance on Cell and Gene Therapy; What Questions Did They Answer? (Part 1)

FDA Law Blog: Biosimilars

The draft guidance includes FAQs covering topics from across disciplines: regulatory review; chemistry, manufacturing, and controls (CMC); nonclinical and pharmacology/toxicology (PT); clinical; and clinical pharmacology.

article thumbnail

Zydus gets Orphan Drug Designation from USFDA for ZYIL1 to treat Cryopyrin Associated Periodic Syndrome

Express Pharma

In September 2022, Zydus had announced positive Phase 2 proof-of-concept (POC) study in CAPS patients, and the publication of Phase 1 study results in Clinical Pharmacology in Drug Development, supporting the advancement of ZYIL1 into pivotal clinical trials in CAPS patients.

article thumbnail

14th Annual RNA Therapeutics Conference

pharmaphorum

In 2023 we will see the return of SAE’s RNA Therapeutics conference to a live in-person event, showcasing an update on mRNA therapeutic applications, coupled with an industry outlook of the field. Director, Clinical Pharmacology. Clinical Science Director. Chief Medical Officers. Chief Technical Officers. Head of Biology.

article thumbnail

The future of medical cannabis development in Europe

European Pharmaceutical Review

5 When these medicines are prescribed to patients, we can use feedback from the real-world data that documents clinical outcomes, efficacy measures, patient-reported outcomes, and adverse events. An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry.